Literature DB >> 19112401

Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria.

Michael Maes1, Jean-Claude Leunis.   

Abstract

BACKGROUND: There is now evidence that an increased translocation of LPS from gram negative bacteria with subsequent gut-derived inflammation, i.e. induction of systemic inflammation and oxidative & nitrosative stress (IO&NS), is a new pathway in chronic fatigue syndrome (CFS).
METHODS: The present study examines the serum concentrations of IgA and IgM to LPS of gram-negative enterobacteria, i.e. Hafnia Alvei; Pseudomonas Aeruginosa, Morganella Morganii, Pseudomonas Putida, Citrobacter Koseri, and Klebsielle Pneumoniae in CFS patients both before and after intake of natural anti-inflammatory and anti-oxidative substances (NAIOSs), such as glutamine, N-acetyl cysteine and zinc, in conjunction with a leaky gut diet during 10-14 months. We measured the above immune variables as well as the Fibromyalgia and Chronic Fatigue Syndrome Rating Scale in 41 patients with CFS before and 10-14 months after intake of NAIOSs.
RESULTS: Subchronic intake of those NAIOSs significantly attenuates the initially increased IgA and IgM responses to LPS of gram negative bacteria. Up to 24 patients showed a significant clinical improvement or remission 10-14 months after intake of NAIOSs. A good clinical response is significantly predicted by attenuated IgA and IgM responses to LPS, the younger age of the patients, and a shorter duration of illness (< 5 years). DISCUSSION: The results show that normalization of the IgA and IgM responses to translocated LPS may predict clinical outcome in CFS. The results support the view that a weakened tight junction barrier with subsequent gut-derived inflammation is a novel pathway in CFS and that it is a new target for drug development in CFS. Meanwhile, CFS patients with leaky gut can be treated with specific NAIOSs and a leaky gut diet.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19112401

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  42 in total

1.  Role of Glutamine in Protection of Intestinal Epithelial Tight Junctions.

Authors:  RadhaKrishna Rao; Geetha Samak
Journal:  J Epithel Biol Pharmacol       Date:  2012-01

Review 2.  The gut microbiome and the brain.

Authors:  Leo Galland
Journal:  J Med Food       Date:  2014-12       Impact factor: 2.786

Review 3.  Zinc and gastrointestinal disease.

Authors:  Sonja Skrovanek; Katherine DiGuilio; Robert Bailey; William Huntington; Ryan Urbas; Barani Mayilvaganan; Giancarlo Mercogliano; James M Mullin
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

4.  Protective effect of glutamine on intestinal injury and bacterial community in rats exposed to hypobaric hypoxia environment.

Authors:  Chun-Lan Xu; Rui Sun; Xiang-Jin Qiao; Cui-Cui Xu; Xiao-Ya Shang; Wei-Ning Niu
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

5.  Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease?

Authors:  Lorenza Conterno; Francesca Fava; Roberto Viola; Kieran M Tuohy
Journal:  Genes Nutr       Date:  2011-05-11       Impact factor: 5.523

6.  From "Leaky Gut" to Impaired Glia-Neuron Communication in Depression.

Authors:  Leszek Rudzki; Michael Maes
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Review part 2: Human herpesvirus-6 in central nervous system diseases.

Authors:  Karen Yao; John R Crawford; Anthony L Komaroff; Dharam V Ablashi; Steven Jacobson
Journal:  J Med Virol       Date:  2010-10       Impact factor: 2.327

Review 8.  Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways.

Authors:  Michael Maes; Frank N M Twisk
Journal:  BMC Med       Date:  2010-06-15       Impact factor: 8.775

9.  Longitudinal associations of lymphocyte subsets with clinical outcomes in chronic fatigue syndrome.

Authors:  Melissa L Mehalick; Karen B Schmaling; Daniel E Sabath; Dedra S Buchwald
Journal:  Fatigue       Date:  2018-01-12

10.  A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome.

Authors:  A Venket Rao; Alison C Bested; Tracey M Beaulne; Martin A Katzman; Christina Iorio; John M Berardi; Alan C Logan
Journal:  Gut Pathog       Date:  2009-03-19       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.